Adults ≥ 40 years with CKD stages 1-5 and HF [LVEF > 40%; excluding end-stage renal disease (ESRD) or dialysis] receiving finerenone were compared with those on SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is chronic kidney disease.